Peop loss medications could reduce the symptoms of the painful skin condition, the study finds

It has been shown that LPG-1 weight loss and diabetes medications, such as Ozempic and the couple, reduce the symptoms of a painful skin condition.

Suppurative hydramentitis, also known as reverse acne, is a condition that makes small painful packages under the skin develop, according to Mayo Clinic.

These packages usually develop in areas of the body where the skin rubs and can be recurrent.

Popular weight loss medication could relieve painful arthritis symptoms, doctors report

Suppurative hydramentitis tends to begin after puberty and before the age of 40, persisting for many years and potentially worsening over time, according to Mayo Clinic. Women have three times more likely to develop the condition.

Medical and surgical therapy can help control the condition and prevent complications.

A new study, published in Jama Dermatology magazine, analyzed how GLP-1 medication could affect this skin condition.

French researchers pointed out that suppurative hydradenitis is typically associated with overweight and obesity, which affects 50% of these patients.

Who should take medications to lose weight? Doctors share the best candidates

Experts pointed out that weight loss, either through a diet or obesity surgery, has a “beneficial effect” in the condition of the skin for most patients.

As LPG-1 have demonstrated an “important effectiveness” in weight loss, researchers raised the hypothesis that medications could also have anti-inflammatory properties that can help with skin symptoms.

The study evaluated 66 patients with suppurative hydramentitis who were taking a GLP-1 medication, following an average of 18.5 months later.

Almost 90% of the study participants had diabetes, and their average BMI was 39.4. The treatment for skin condition began for 53% of patients.

Ozempic is ruining your teeth? What to know about the impact on dental health

After six months, 54% of patients had a reduction in symptoms.

In the last consultation, 67% of the participants reported reductions and 60% had a decreased pain.

‘Cautious optimism’

Dr. Brendan Camp, a dermatologist in New York, reacted to these study findings with “cautious optimism.”

“It is impressive that, in a median of 18.5 months of monitoring, the agonists of the GLP-1 receiver led to significant reductions in the severity of HS, the flares and the pain in patients, most of which were obese and had diabetes,” he said in an interview with News Digital.

Click here to register in our health newsletter

Camp confirmed how weight loss with the help of LPG-1 can reduce “mechanical friction” and “inflammation driven by adipose in susceptible areas” where skin conditions can occur.

LPG-1 also seem to have anti-inflammatory effects, which could improve skin healing and reduce the frequency of inflammatory skin diseases, he said.

Potential limitations

Camp said that although the study represents a “promising therapeutic signal”, its retrospective design “limits the causal conclusions.”

“Solid confirmation through random clinical trials is of vital importance,” he said.

Click here to get the News application

In addition, the majority of participants in the study were obese and diabetic, which means that the results may not be applicable to all patients with suppurative hydramentitis.

“Future random essays are required to determine who will benefit more and establish the safety and effectiveness in the broader HS population,” Camp said.

“LPG-1 therapies remain investigative of suppurative hydramentitis and are not an approved indication.”

The dermatologist currently does not recommend LPG-1 only for suppurative hydramentitis or other skin conditions.

“Patients with HS should know that, although these findings have hopes, showing improvements in gravity, the frequency of the sprinkle, pain and quality of life during the months of treatment, LPG-1 therapies remain investigative for HS and are not an approved indication,” he said.

For more health articles, visit Newsnews.com/health

However, those who qualify for LPG-1 treatment for diabetes or obesity can find that these medications offer the “additional potential benefit to improve HS symptoms.”

“The initiation out of label should be addressed without a clear indication with caution (weighing costs, side effects and lack of definitive evidence of trials, and only under the guidance of a dermatologist and a prescription provider,” Camp added.